AION Labs, Powered by BioMed X, Launches Third Global Call for Application: Artificial Intelligence for Design and Optimization of Antibodies for Targeted Therapies
- AION Labs, Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS), to start third global crowdsourcing initiative based on the innovation model of Germany’s BioMed X Institute
- Call for application seeks to identify global research talent for new startup company in field of: AI Enabled Design and Optimization of Antibodies for Targeted Therapies
Rehovot, Israel and Heidelberg, Germany – February 14, 2022 – AION Labs, a first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced today the launch of the third global call for application to identify biomedical scientists and inventors to form a new startup at AION Labs’ headquarters in Rehovot, Israel.
The chosen AION Labs startup team will be sponsored by several industry-leading partners and supported by the Israel Innovation Authority (IIA) and Digital Israel office. The sponsors of this call for application are AstraZeneca, Israel Biotech Fund, Merck, and Pfizer and Teva Pharmaceuticals, with close support from Amazon Web Services (AWS).
Antibody treatments continue to be the standard of care for several disease areas and have emerged as cornerstone therapies during the current pandemic. However, despite being primary treatment modalities for over two decades, the cycle times for the discovery and optimization of therapeutic antibodies can still span several years. In order to achieve developable antibody therapeutics exhibiting target-specific binding, stability and scalability, several biophysical parameters need to be streamlined.The use of artificial intelligence (AI) has the potential to broaden the explored sequence space, accelerate the selection of fully optimized antibodies, and shorten overall lead discovery times by successfully predicting relevant parameters.
AION Labs is inviting computational biologists, bioinformatics and cheminformatics scientists, AI researchers, and antibody or protein engineers at academic and industry research labs worldwide to propose the development of a next-generation computational platform to optimize antibodies for targeted therapies with enhanced properties, including developability or manufacturability, stability, aggregation, immunogenicity, pharmacokinetics and tissue distribution. The ultimate solution is an AI platform that receives sequences of binders and generates novel variants with optimized IgG sequences, biophysical and targeting properties. The goal of the AI algorithm is to make an existing antibody a better drug while reducing design iterations, optimization of cycle times and lowering attrition rates.
The AION Labs pharma partners involved in this project will provide a wealth of data for model training and their expertise in setting specifications and evaluating the outcome. Original ideas that go far beyond the current state-of-the-art are being encouraged.
“AION Labs is eager to tackle yet another pharmaceutical R&D challenge,” says Dr. Yair Benita, CTO of AION Labs. “We’re anticipating another strong round of applications, and look forward to working together with the chosen startup to develop a cutting-edge solution to substantially improve the design and optimization of antibodies for targeted therapies.”
As part of the online application procedure, interested candidates are requested to submit a competitive project proposal. After a preliminary short-listing round, candidates will be invited to a five-day innovation boot camp in Rehovot. With the support of experienced mentors from the pharma, tech and VC industries, the winning team of scientists will be trained and guided during a fully-funded incubation period of up to four years towards becoming an independent startup.
Further details about this call for application can be found on the AION Labs website: www.aionlabs.com. Interested candidates are invited to apply via the BioMed X Career Space at https://career.bio.mx/call/2022-AIL-C03 before April 10, 2022.
Candidates are also invited to sign up for an informative webinar to learn more about AION Labs and this challenge on March 10, 2022 at 5 PM CET. Registration can be made here https://bit.ly/3oFwMIO
About AION Labs
AION Labs is a first-of-its-kind alliance of AstraZeneca, Merck, Pfizer, Teva, the Israel Biotech Fund and Amazon Web Services (AWS) that have come together with one clear mission: to create and adopt groundbreaking new AI technologies that will transform the process of drug discovery and development in order to contribute to the health and well-being of all people world-wide.
AION Labs is a unique venture hub where brilliant innovators and scientist-founders convene from around the world to solve the biggest R&D challenges guided by years of accumulated know-how, data and experience in pharma. The lab leverages its partners’ wealth of knowledge and a new multidisciplinary mindset with the ingenuity, agility and innovative power of Israel’s start-up ecosystem, to develop strong companies with clear long-term strategies, that will pave the way to the future of healthcare. AION Labs cultivates innovation from within; its unique venture creation process bridges the gap between outstanding academic research in the field of AI and the biggest R&D needs in the discovery and development of new medicines for the benefit of patients.
For more information, visit aionlabs.com
FINN Partners for AION Labs
+1 929 588 2016
+972 54 282 4503